Prescribing principles (all classes)
- Establish a diagnosis + identify target symptoms to monitor response; pick an agent by side-effect profile; use the lowest effective dose
- Informed consent (benefits/risks; document teratogenicity discussion in fertile women); run a monitoring programme (compliance, side effects, target-symptom response, blood levels/tests); keep the simplest effective regimen
1. Antipsychotics
- Indication: psychosis/schizophrenia — start promptly (delay worsens negative symptoms); part of an individualised plan with psychosocial support; depot (long-acting injection) if concordance is poor
- Mechanism: block/partially block dopamine D2 receptors in the mesolimbic area; all show D2 antagonism (drives efficacy)
| Generation | Receptor action | Examples | Trade-off |
| 1st (FGA, typical) | D2 antagonist | Haloperidol, trifluoperazine | EPSE (nigrostriatal D2 block) |
| 2nd (SGA, atypical) | 5-HT2A + D2 antagonist | Clozapine, olanzapine, quetiapine, risperidone | Less EPSE, more metabolic SE |
| 3rd (TGA) | Dopamine partial agonist | Aripiprazole (first), brexpiprazole, cariprazine, lumateperone | — |
- Neurological SE (esp. FGA): acute dystonic reaction (emergency); parkinsonism (rigidity, bradykinesia, tremor); akathisia (emergency — restlessness); tardive dyskinesia (prolonged use — involuntary face/mouth/tongue movements); neuroleptic malignant syndrome (emergency — fever, muscle rigidity, tachycardia, CK >1000)
- Non-neurological SE: anticholinergic (dry mouth, blurred vision, constipation, urinary retention); arrhythmia; orthostatic hypotension; weight gain (antihistaminic); raised prolactin (impotence, amenorrhoea)
- Newer drugs: weight gain, sexual dysfunction (raised prolactin), postural hypotension + long QTc, daytime drowsiness; clozapine → agranulocytosis/neutropenia (mandatory FBC monitoring) + myocarditis/cardiomyopathy
2. Antidepressants
- Indication: major depression (esp. relapse prevention); CBT is as effective as drugs in mild–moderate, combined is best; warn of initial worsening before benefit; full efficacy takes ~6 weeks; monitor suicidality early; assess formally at ≥4 weeks; if effective continue ≥6 months after recovery (stopping early → 50% relapse)
- Mechanism: raised synaptic neurotransmitter → receptor desensitisation/down-regulation + gene-expression changes → clinical effect after weeks; SSRIs block serotonin reuptake
- Response: switching > augmenting; little dose–response evidence — don't just keep increasing the dose; switch class if no response by 4 weeks
| Class | Examples | Notes |
| SSRI (first-line) | Fluoxetine, citalopram/escitalopram, sertraline (best in IHD) | Low start, titrate; monitor FBC (GI bleed — avoid NSAIDs) + U&E (hyponatraemia); citalopram → dose-dependent QTc prolongation (ECG; Torsades risk) |
| NaSSA | Mirtazapine | Drowsy at low dose → useful as evening dose to aid sleep |
| SNRI | Venlafaxine | Mixed anxiety; needs baseline BP + ECG (CVS effects) |
| TCA (4th line) | Nortriptyline, clomipramine | Older; dangerous in overdose |
| MAOI (4th line) | Moclobemide | Older; rarely used |
Lithium is an effective adjunct but has significant toxicity. Common antidepressant SE: nausea, weight gain, sexual dysfunction, fatigue/drowsiness or insomnia, anticholinergic effects.
3. Mood stabilisers
- Indication: bipolar affective disorder (acute mania / depressive episode / prophylaxis); only ~1/3 respond to monotherapy. Onset: lithium ≥1 week; valproate + antipsychotics (olanzapine, aripiprazole) act faster in acute mania (bridge with antipsychotics/sedatives until the stabiliser works)
| Agent | Mechanism | Key side effects / cautions |
| Lithium | Signal transduction (2nd-messenger enzyme inhibition, G-protein modulation, GSK3 inhibition) | Narrow therapeutic index — monitor levels; GI, polyuria/polydipsia, lethargy, weight gain, tremor, acne, oedema (Na retention), hypothyroidism/goitre; avoid dehydration (→ toxicity, fatal if unchecked) |
| Sodium valproate | Blocks Na channels + raises GABA | First-line (esp. mixed/rapid-cycling); teratogenic (spina bifida, cardiac, cleft lip) → avoid in women of childbearing age; sedation, tremor, headache, weight gain, lipid dysregulation, alopecia |
| Carbamazepine | Blocks Na channels (↓ glutamate) | Acute mania + prophylaxis (efficacy < lithium); GI, sedation, ataxia, severe bone-marrow depression; hepatic P450 induction → fails OCP + warfarin |
| Lamotrigine | Na-channel antagonist (↓ glutamate) | Better for bipolar depression; life-threatening skin reactions incl. Stevens-Johnson (first 2–8 weeks or on abrupt stop–restart) |
4. Anxiolytics
- Indication: panic disorder, GAD, substance withdrawal, insomnia/parasomnias; often combined with an SSRI/SNRI in anxiety disorders
- Benzodiazepines — insomnia, parasomnias, anxiety; SE somnolence, amnesia, disinhibition; dependence + tolerance → use sparingly, short-term only
- Beta-blockers (propranolol) — improve somatic anxiety (tremor, sweating; e.g. public speaking); do not help cognitive anxiety
- Buspirone — GAD; high-affinity 5-HT1A agonist (not GABA); non-sedating; takes ~4 weeks; not for acute anxiety/panic
Compliance
- No improvement → check efficacy/tolerance, rethink the diagnosis, check drug–drug interactions, and confirm the drug is actually being taken
- Reasons for non-compliance: side effects seen as worse than the illness, stigma, medication as a reminder of being ill, belief that it doesn't work